Valproic acid Population Pharmacokinetics in Asian Pediatric Epileptics: A Systematic Review

Muh. Faris Hidayat; Purwantiningsih Purwantiningsih; Rizaldy Taslim Pinzon

doi:10.22146/farmaseutik.v20i4.96233

Valproic acid Population Pharmacokinetics in Asian Pediatric Epileptics: A Systematic Review

https://doi.org/10.22146/farmaseutik.v20i4.96233

Muh. Faris Hidayat⁽¹⁾, Purwantiningsih Purwantiningsih^(2*), Rizaldy Taslim Pinzon⁽³⁾

(1) Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada
(2) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada
(3) Neurology Department, Bethesda Hospital, Yogyakarta
(*) Corresponding Author

Abstract

The pharmacokinetic profile of valproic acid in pediatric subjects in Asian populations is lacking. One of the most useful ways to develop a personalized dosing strategy is to use population pharmacokinetics. The focus of this systematic review is to describe the population pharmacokinetic profile of valproic acid (VPA) and determine the variables influencing pharmacokinetic models of the drug in children with epilepsy that have been published in Asian journals. A comprehensive literature search was carried out from 2014 to 2024 on Science Direct and PubMed. Keywords used valproic acid, valproic, VPA, sodium valproate and population pharmacokinetic, pharmacokinetic model. In this review, four studies were considered. The pharmacokinetic model was developed by looking at several covariates that significantly affect the population pharmacokinetics of VPA using TDM data from pediatric epilepsy patients. The clearance value and volume of distribution of VPA can be seen to be in the range of 0.148 - 3.19 L/h, and 0.317 - 24 L/KgBB. In addition, subjects with SCN1A A/A genotype showed a decreased therapeutic effect of VPA. Significant covariates affecting the pharmacokinetics of VPA were age, dose, and the use of comedication with other anti-seizure drugs.

Keywords

Epilepsy; Pediatric; population pharmacokinetics; valproic acid

Full Text:

PDF

References

Bauer, L. A. (2008). Applied clinical pharmacokinetics (2nd ed). McGraw-Hill Medical.

Bondareva, I. B., Jelliffe, R. W., Andreeva, O. V., & Bondareva, K. I. (2011). Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy: Carbamazepine and valproate therapies. Journal of Clinical Pharmacy and Therapeutics, 36(5), 625–636. https://doi.org/10.1111/j.1365-2710.2010.01215.x

Ding, J., Wang, Y., Lin, W., Wang, C., Zhao, L., Li, X., Zhao, Z., Miao, L., & Jiao, Z. (2015). A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation. Clinical Pharmacokinetics, 54(3), 305–317. https://doi.org/10.1007/s40262-014-0212-8

Eiji Yukawa, Yukawa, E., Hideto To, To, H., Shigehiro Ohdo, Ohdo, S., Shun Higuchi, Higuchi, S., Toshinobu Aoyama, & Aoyama, T. (1997). Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: Influence of drug-drug interaction and patient characteristics. The Journal of Clinical Pharmacology, 37(12), 1160–1167. https://doi.org/10.1002/j.1552-4604.1997.tb04301.x

Gu, X., Zhu, M., Sheng, C., Yu, S., Peng, Q., Ma, M., Hu, Y., Li, Z., Jiao, Z., & Zhou, B. (2021). Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: A protein binding model. European Journal of Clinical Pharmacology, 77(7), 999–1009. https://doi.org/10.1007/s00228-020-03080-y

Heinzen, E. L., Yoon, W., Tate, S. K., Sen, A., Wood, N. W., Sisodiya, S. M., & Goldstein, D. B. (2007). Nova2 Interacts with a Cis-Acting Polymorphism to Influence the Proportions of Drug-Responsive Splice Variants of SCN1A. The American Journal of Human Genetics, 80(5), 876–883. https://doi.org/10.1086/516650

Methaneethorn, J. (2018). A systematic review of population pharmacokinetics of valproic acid. British Journal of Clinical Pharmacology, 84(5), 816–834. https://doi.org/10.1111/bcp.13510

Nakashima, H., Oniki, K., Nishimura, M., Ogusu, N., Shimomasuda, M., Ono, T., Matsuda, K., Yasui-Furukori, N., Nakagawa, K., Ishitsu, T., & Saruwatari, J. (2015). Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis. PLOS ONE, 10(10), e0141266. https://doi.org/10.1371/journal.pone.0141266

Nugraha, I. K. P. N., Anita Purnamayanti, Purnamayanti, A., I Gusti Ngurah Made Suwarba, Suwarba, I. G. N. M., Nani Parfati, & Parfati, N. (2021). Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients. Journal of Basic and Clinical Physiology and Pharmacology, 32(4), 305–311. https://doi.org/10.1515/jbcpp-2020-0488

Romoli, M., Mazzocchetti, P., D’Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019). Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology, 17(10), 926–946. https://doi.org/10.2174/1570159X17666181227165722

Teixeira-da-Silva, P., Pérez-Blanco, J. S., Santos-Buelga, D., Otero, M. J., & García, M. J. (2022). Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients. Pharmaceutics, 14(4), 811. https://doi.org/10.3390/pharmaceutics14040811

Yukawa, E. (2011). A Feasibility Study of the Multiple-peak Approach for Pharmacokinetic Screening: Population-based Investigation of Valproic Acid Relative Clearance Using Routine Clinical Pharmacokinetic Data. Journal of Pharmacy and Pharmacology, 47(12A), 1048–1052. https://doi.org/10.1111/j.2042-7158.1995.tb03295

DOI: https://doi.org/10.22146/farmaseutik.v20i4.96233